Evidence map›Paper›PMID 37338299›Full record

ArticlemBio2023

Leveraging the human microbiota to target bacterial respiratory pathogens: new paths toward an expanded antimicrobial armamentarium.

Jillian H Hurst, Matthew S Kelly

Open access · goldAbstract readComment
In one paragraph

Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

  • Comment on
    2023
5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jillian H HurstDepartment of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA.
Matthew S KellyDepartment of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA.ORCID 0000-0001-8819-2315
Duke University · US

Funding

Clinical and host microbiome features in the development of acute otitis mediaK01AI173398 · NIAID · DUKE UNIVERSITY · PI Jillian Heyward Hurst · 2023 to 2026
$509k
NIAID NIH HHS K01 AI173398
6 · The paper itself

Abstract

Acute respiratory infections are the most frequent infections across the lifespan and are the leading infectious cause of death among children globally. Bacterial respiratory infections are routinely treated with antibiotics, nearly all of which are derived from microbial natural products. Unfortunately, antibiotic-resistant bacteria are an increasingly frequent cause of respiratory infections, and there are few new antibiotics in development that target these pathogens. In the article by Stubbendieck et al., the authors identified

Indexed as

Anti-Infective AgentsRespiratory Tract InfectionsAnti-Bacterial AgentsChildEndopeptidasesHumansMoraxella catarrhalisAnti-Bacterial AgentsAnti-Infective AgentsEndopeptidasespeptidoglycan endopeptidaseacute otitis mediaantibiotic resistancecomparative genomicshuman microbiomemicrobial ecologyMoraxella catarrhalisrespiratory pathogensRothia species

Identifiers

PMID37338299
PMCPMC10470731
OpenAlexW4381309517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.